Palbociclib has recently been FDA approved for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor (HER)2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This evidence concerns the gene ESR1 and metastatic neoplasm.